Abstract

 Given the current rapid growth in the gene therapy sector, it is imperative that downstream processing doesn’t apply a handbrake to recent gains made in increasing AAV vector upstream process scale and titer. In a recent webinar, a panel of AAV vector processing experts discussed whether the potentially conflicting drivers of increasing the efficiency versus the sensitivity and robustness of downstream vector processing is reflected in today’s purification toolkit, and asked ‘what’s next?’ in terms of further development. Here, we sum up some of their key thoughts. 

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call